Inhibition of EZH2 Ameliorates Lupus-Like Disease in MRL/lpr Mice.

Dallas M RohraffYe HeEvan A FarkashMark SchonfeldPei-Suen TsouAmr Hakam Sawalha

Published in: Arthritis & rheumatology (Hoboken, N.J.) (2019)

EZH2 is up-regulated in multiple cell types in lupus patients. Therapeutic inhibition of EZH2 abrogates lupus-like disease in MRL/lpr mice, suggesting that EZH2 inhibitors may be repurposed as a novel therapeutic option for lupus patients.

Keyphrases

systemic lupus erythematosus
end stage renal disease
newly diagnosed
ejection fraction
disease activity
chronic kidney disease
long non coding rna
prognostic factors
long noncoding rna
type diabetes
stem cells
transcription factor
single cell
metabolic syndrome
cell therapy